US6117641A
(en)
|
1996-04-11 |
2000-09-12 |
Mitotix, Inc. |
Assays and reagents for identifying anti-fungal agents and uses related thereto
|
AU717165B2
(en)
|
1996-04-11 |
2000-03-16 |
Gpc Biotech Inc. |
Assays and reagents for identifying anti-fungal agents, and uses related thereto
|
US6727082B1
(en)
|
1996-04-11 |
2004-04-27 |
Gpc Biotech Inc. |
Assays and reagents for identifying anti-fungal agents, and uses related thereto
|
AU709409B2
(en)
*
|
1996-07-15 |
1999-08-26 |
Bristol-Myers Squibb Company |
Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
|
EP1019529A4
(en)
*
|
1997-08-27 |
2002-09-11 |
Merck & Co Inc |
METHOD FOR TREATING CANCER
|
CA2304473A1
(en)
*
|
1997-09-29 |
1999-04-22 |
Rajeev S. Bhide |
Inhibitors of farnesyl protein transferase
|
US6458783B1
(en)
*
|
1997-09-29 |
2002-10-01 |
Bristol-Myers Squibb Company |
Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
|
DE1049664T1
(de)
*
|
1997-12-22 |
2001-05-03 |
Bayer Corp., Pittsburgh |
Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
|
US6071903A
(en)
*
|
1998-01-27 |
2000-06-06 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
|
US6423519B1
(en)
|
1998-07-15 |
2002-07-23 |
Gpc Biotech Inc. |
Compositions and methods for inhibiting fungal growth
|
AU2478500A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6284755B1
(en)
|
1998-12-08 |
2001-09-04 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
ATE556713T1
(de)
|
1999-01-13 |
2012-05-15 |
Bayer Healthcare Llc |
Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
CA2359646C
(en)
*
|
1999-01-21 |
2008-12-02 |
Bristol-Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-.beta.-cyclodextrin or 2-hydroxypropyl-.beta.-cyclodextrin and method
|
EP1158982A4
(en)
*
|
1999-03-03 |
2002-06-12 |
Merck & Co Inc |
Prenyl protein transferase inhibitors
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
MXPA01010292A
(es)
|
1999-04-15 |
2002-10-23 |
Squibb Bristol Myers Co |
Inhibidores ciclicos de la proteina tirosina cinasa.
|
US20060025388A1
(en)
|
1999-04-30 |
2006-02-02 |
Glick Gary D |
Compositions and methods relating to novel compounds and targets thereof
|
US20020115696A1
(en)
|
1999-06-18 |
2002-08-22 |
Yoel Kloog |
Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
|
JP2003502365A
(ja)
*
|
1999-06-18 |
2003-01-21 |
サイリオス・コーポレイション |
Rasアンタゴニストによる非悪性疾患処置
|
NZ516467A
(en)
|
1999-06-30 |
2004-03-26 |
Prescient Neuropharma Inc |
A method of treating diseases of the central nervous system (CNS) with 2-aminoindane analogues
|
FR2796943A1
(fr)
*
|
1999-07-30 |
2001-02-02 |
Aventis Pharma Sa |
Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
|
EP1088821A1
(en)
*
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmaceutically active sulfonamide derivatives
|
US6100395A
(en)
*
|
2000-01-10 |
2000-08-08 |
Bristol-Myers Squibb Company |
Reductive alkylation of secondary amines with hydrosilane
|
DE60130976T2
(de)
|
2000-02-24 |
2008-07-17 |
Janssen Pharmaceutica N.V. |
Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
|
TWI310684B
(en)
*
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
WO2001076629A1
(fr)
*
|
2000-04-07 |
2001-10-18 |
Takeda Chemical Industries, Ltd. |
Promoteurs solubles de secretion du precurseur de la proteine beta-amyoide
|
AU2002214056A1
(en)
*
|
2000-11-21 |
2002-06-03 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting benzoheterocyclic derivatives
|
DE60118953T2
(de)
*
|
2000-11-28 |
2007-01-11 |
Janssen Pharmaceutica N.V. |
Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
|
ES2260316T3
(es)
*
|
2000-12-27 |
2006-11-01 |
Janssen Pharmaceutica N.V. |
Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
|
WO2002051834A1
(en)
*
|
2000-12-27 |
2002-07-04 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives
|
US6645966B2
(en)
*
|
2001-01-22 |
2003-11-11 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
DE60225666T2
(de)
|
2001-01-25 |
2009-04-16 |
Bristol-Myers Squibb Co. |
Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
|
US7759323B2
(en)
|
2001-05-22 |
2010-07-20 |
Eisai R & D Management Co., Ltd. |
Highly purified antiendotoxin compound
|
EP1288713A1
(en)
*
|
2001-08-29 |
2003-03-05 |
Chugai Photo Chemical Co. Ltd. |
Processing agent for silver halide color photosensitive material and processing method thereof
|
US20030134846A1
(en)
*
|
2001-10-09 |
2003-07-17 |
Schering Corporation |
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
|
US7074921B2
(en)
*
|
2001-11-13 |
2006-07-11 |
Bristol Myers Squibb Company |
Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
|
ES2378670T3
(es)
|
2002-02-11 |
2012-04-16 |
Bayer Healthcare, Llc |
Aril ureas como inhibidores de cinasas
|
PT1478358E
(pt)
|
2002-02-11 |
2013-09-11 |
Bayer Healthcare Llc |
Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
|
WO2003077656A1
(en)
*
|
2002-03-15 |
2003-09-25 |
Ciba Specialty Chemicals Holding Inc. |
4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
|
US7405234B2
(en)
*
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
CA2487866A1
(en)
*
|
2002-06-07 |
2003-12-18 |
Cortical Pty Ltd |
Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
|
US20040009972A1
(en)
*
|
2002-06-17 |
2004-01-15 |
Ding Charles Z. |
Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
|
WO2004015130A2
(en)
*
|
2002-08-07 |
2004-02-19 |
Exelixis |
Modulators of rabggt and methods of use thereof
|
WO2004045518A2
(en)
*
|
2002-11-15 |
2004-06-03 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
JP2004346059A
(ja)
*
|
2003-01-28 |
2004-12-09 |
Takeda Chem Ind Ltd |
受容体作動薬
|
WO2004067008A1
(ja)
*
|
2003-01-28 |
2004-08-12 |
Takeda Pharmaceutical Company Limited |
受容体作動薬
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
CA2526617C
(en)
|
2003-05-20 |
2015-04-28 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas with kinase inhibiting activity
|
AU2004259760B9
(en)
|
2003-07-23 |
2011-02-03 |
Bayer Healthcare Llc |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
US20050069553A1
(en)
|
2003-08-13 |
2005-03-31 |
Yi Zheng |
Chimeric peptides for the regulation of GTPases
|
EP1656156A2
(en)
|
2003-08-13 |
2006-05-17 |
Children's Hospital Medical Center |
Mobilization of hematopoietic cells
|
US7256208B2
(en)
*
|
2003-11-13 |
2007-08-14 |
Bristol-Myers Squibb Company |
Monocyclic N-Aryl hydantoin modulators of androgen receptor function
|
EP1691812A4
(en)
|
2003-11-20 |
2010-01-13 |
Childrens Hosp Medical Center |
GTPASE INHIBITORS AND METHOD OF USE
|
US20050182105A1
(en)
*
|
2004-02-04 |
2005-08-18 |
Nirschl Alexandra A. |
Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7388027B2
(en)
*
|
2004-03-04 |
2008-06-17 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
WO2005089504A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
WO2005089496A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089518A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Uch-l1 expression and cancer therapy
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
CA2559285A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US7323455B2
(en)
*
|
2004-03-24 |
2008-01-29 |
Wyeth |
7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
|
US20050272723A1
(en)
*
|
2004-04-27 |
2005-12-08 |
The Regents Of The University Of Michigan |
Methods and compositions for treating diseases and conditions associated with mitochondrial function
|
US10675326B2
(en)
|
2004-10-07 |
2020-06-09 |
The Board Of Trustees Of The University Of Illinois |
Compositions comprising cupredoxins for treating cancer
|
SI2362218T1
(sl)
|
2004-11-05 |
2014-12-31 |
Janssen Pharmaceutica N.V. |
Postopki za spremljanje učinkovitosti inhibitorjev farneziltransferaze
|
DE602005007376D1
(de)
|
2004-11-18 |
2008-07-17 |
Bristol Myers Squibb Co |
Magensaftresistent beschichtetes pellet mit ixabepilon
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
CA2602351A1
(en)
*
|
2005-03-25 |
2006-10-05 |
Kissei Pharmaceutical Co., Ltd. |
Urea derivative, medicinal composition containing the same, and medicinal use of these
|
US20060235006A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
EP1879881A2
(en)
*
|
2005-04-14 |
2008-01-23 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
|
EP1909795B1
(en)
*
|
2005-06-09 |
2011-04-13 |
Bristol-Myers Squibb Company |
Pharmaceutical composition for use in treating individuals exhibiting mutant kit protein
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
AU2006275528B2
(en)
|
2005-07-29 |
2012-03-08 |
Children's Hospital Medical Center |
GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
|
WO2007024949A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Schering Corporation |
Alpha2c adrenoreceptor agonists
|
US7700592B2
(en)
*
|
2005-08-25 |
2010-04-20 |
Schering Corporation |
α2C adrenoreceptor agonists
|
JP5185120B2
(ja)
|
2005-09-16 |
2013-04-17 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒスタミンh3受容体のモジュレーターとしてのシクロプロピルアミン
|
WO2007059143A2
(en)
*
|
2005-11-15 |
2007-05-24 |
Bristol-Myers Squibb Company |
Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
|
ATE479434T1
(de)
*
|
2006-02-14 |
2010-09-15 |
Vertex Pharma |
Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
MX2008013533A
(es)
|
2006-04-20 |
2009-01-15 |
Janssen Pharmaceutica Nv |
Compuestos heterociclicos como inhibidores de c-fms cinasa.
|
ES2566772T3
(es)
|
2006-04-20 |
2016-04-15 |
Janssen Pharmaceutica, N.V. |
Inhibidores de la quinasa c-fms
|
US8017749B2
(en)
|
2006-12-04 |
2011-09-13 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
|
ES2620818T3
(es)
|
2006-12-14 |
2017-06-29 |
Janssen Pharmaceutica N.V. |
Procedimiento para la preparación de derivados de piperazinil y diazepanil benzamida
|
WO2008089135A2
(en)
*
|
2007-01-12 |
2008-07-24 |
University Of South Florida |
Identification of biomarkers predictive of dasatinib effects in cancer cells
|
RU2009133473A
(ru)
|
2007-02-08 |
2011-03-20 |
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) |
Композиции и способы для предотвращения рака с помощью купредоксинов
|
WO2008141081A1
(en)
*
|
2007-05-10 |
2008-11-20 |
Amr Technology, Inc. |
Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
WO2008144981A1
(fr)
*
|
2007-05-25 |
2008-12-04 |
Topharman Shanghai Co., Ltd. |
Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine
|
CL2008001633A1
(es)
|
2007-06-05 |
2008-12-12 |
Schering Corp |
Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
US20110015158A1
(en)
|
2007-12-11 |
2011-01-20 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
ES2637805T3
(es)
*
|
2008-05-05 |
2017-10-17 |
Sanofi |
Derivados de ácido ciclopentanocarboxílico fusionados sustituidos por acilamino y su uso como productos farmacéuticos
|
US8119129B2
(en)
*
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
MX2011005096A
(es)
*
|
2008-11-13 |
2011-11-18 |
Link Medicine Corp |
Derivados de azaquinolinona y usos de los mismos.
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
EP2435426B8
(en)
*
|
2009-05-26 |
2013-07-03 |
Exelixis, Inc. |
BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE
|
WO2010141932A1
(en)
|
2009-06-05 |
2010-12-09 |
Link Medicine Corporation |
Aminopyrrolidinone derivatives and uses thereof
|
ES2629167T3
(es)
|
2009-07-20 |
2017-08-07 |
Bristol-Myers Squibb Company |
Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas
|
AU2010300925A1
(en)
|
2009-09-30 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
JP5856063B2
(ja)
|
2009-11-17 |
2016-02-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
治療特性を有する1,4−ベンゾジアゼピン−2,5−ジオンおよび関連化合物
|
EP2842944B1
(en)
*
|
2010-04-06 |
2017-03-15 |
Nippon Soda Co., Ltd. |
Method for producing nitrogen-containing heterocyclic compound
|
AU2014201038B2
(en)
*
|
2010-04-06 |
2015-08-06 |
Nippon Soda Co., Ltd. |
Nitrogen-containing heterocyclic compound and method for producing same
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
WO2012100206A2
(en)
|
2011-01-20 |
2012-07-26 |
Board Of Regents, The University Of Texas System |
Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
WO2013064231A1
(en)
|
2011-10-31 |
2013-05-10 |
Phenex Pharmaceuticals Ag |
SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
EP2880039B1
(en)
|
2012-07-31 |
2017-01-04 |
Dow Global Technologies LLC |
Method of making an olefin polymerization catalyst activator
|
CN104870454B
(zh)
|
2012-08-07 |
2020-03-03 |
詹森药业有限公司 |
用于制备杂环酯衍生物的方法
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2924044B1
(en)
|
2012-11-17 |
2018-10-31 |
Beijing Shuobai Pharmaceutical Co., LTD |
Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
JP6473133B2
(ja)
*
|
2013-03-15 |
2019-02-20 |
アラクセス ファーマ エルエルシー |
Krasg12cの共有結合性阻害剤
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
MX2017000181A
(es)
|
2014-06-27 |
2017-05-01 |
Univ California |
Celulas madre limbales de mamifero cultivadas, metodos para generarlas y sus usos.
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
KR101885361B1
(ko)
|
2015-08-17 |
2018-08-06 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3377481A1
(en)
|
2015-11-16 |
2018-09-26 |
Araxes Pharma LLC |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
EP4067347B1
(en)
*
|
2016-05-24 |
2024-06-19 |
Genentech, Inc. |
Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
CN110036010A
(zh)
|
2016-09-29 |
2019-07-19 |
亚瑞克西斯制药公司 |
Kras g12c突变蛋白的抑制剂
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
CN110325212B
(zh)
|
2016-11-03 |
2022-03-22 |
库拉肿瘤学公司 |
用于治疗癌症的方法的法尼基转移酶抑制剂
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
TWI663974B
(zh)
|
2017-02-21 |
2019-07-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
BR112020002591A2
(pt)
|
2017-08-07 |
2020-07-28 |
Kura Oncology, Inc. |
método para o tratamento de câncer
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3681885B1
(en)
|
2017-09-15 |
2024-02-28 |
Forma Therapeutics, Inc. |
Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
MX2023013508A
(es)
|
2018-06-29 |
2023-12-13 |
Forma Therapeutics Inc |
Inhibicion de la proteina de union a creb (cbp).
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
EP3873469A2
(en)
|
2018-11-01 |
2021-09-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
CN113365630A
(zh)
|
2018-12-21 |
2021-09-07 |
库拉肿瘤学公司 |
用于鳞状细胞癌的疗法
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
EP3972978A4
(en)
*
|
2019-05-20 |
2023-04-26 |
California Institute Of Technology |
KRAS G12C INHIBITORS AND THEIR USES
|
WO2021220132A1
(en)
|
2020-04-27 |
2021-11-04 |
Novartis Ag |
Methods and compositions for ocular cell therapy
|
US11801243B2
(en)
|
2020-09-23 |
2023-10-31 |
Forma Therapeutics, Inc. |
Bromodomain inhibitors for androgen receptor-driven cancers
|
US11795168B2
(en)
|
2020-09-23 |
2023-10-24 |
Forma Therapeutics, Inc. |
Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
|
CN115745960B
(zh)
*
|
2021-09-02 |
2024-08-30 |
中国科学院上海药物研究所 |
一类含喹啉酮酰胺的化合物及其制备方法、药物组合物和用途
|
CN114230529A
(zh)
*
|
2021-11-03 |
2022-03-25 |
河南大学 |
四氢喹喔啉磺酰胺衍生物及其制备方法与用途
|
CN118556044A
(zh)
*
|
2022-01-29 |
2024-08-27 |
江苏恒瑞医药股份有限公司 |
稠杂环类化合物、其制备方法及其在医药上的应用
|
WO2024097606A1
(en)
*
|
2022-10-31 |
2024-05-10 |
Eli Lilly And Company |
Ahr agonists
|